Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

AGILENT TECHNOLOGIES, INC.

(A)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Agilent Technologies : Resolution Bioscience (a part of Agilent) Investigated Acquired Resistance to KRAS G12C Inhibition

06/28/2021 | 08:06am EST

Liquid biopsy techniques uncover acquired resistance mechanisms to KRAS G12C inhibitors

Agilent Technologies Inc. (NYSE: A) today announced the publication of a study carried out in partnership with Resolution Bioscience (a part of Agilent) and Dana-Farber Cancer Institute. The paper was published in the New England Journal of Medicine (NEJM) on June 24 and is titled "Acquired Resistance to KRAS G12C Inhibition in Cancer." It demonstrates the clinical utility of liquid biopsy techniques to detect resistance to targeted therapies, including inhibitors of KRAS, one of the most commonly mutated oncogenes in cancer.

KRAS G12C inhibitors, such as adagrasib, have shown promising efficacy in clinical trials, however, mechanisms of acquired resistance are not yet fully understood. Leveraging cell-free DNA (cfDNA) analysis, this study was conducted to investigate mutations that arise that may confer resistance to patients treated with KRAS inhibitors, including adagrasib and to better understand the process of acquired resistance and to identify new strategies to combat acquired resistance.

The results of the study showed KRAS G12C cancers have diverse genomic and histologic mechanisms, including point mutations, copy number changes, and fusions, that appear to impart resistance to KRAS G12C inhibitors. Developing therapeutic strategies to delay and overcome drug resistance will be an essential component in improving therapeutic outcomes in cancer patients.

“While results from these early clinical trials are encouraging, the cancer usually becomes resistant to these drugs,” said Dana-Farber’s Mark Awad, MD, Ph.D., the co-first author of the paper with Shengwu Liu, Ph.D., also of Dana-Farber. “The mechanisms of resistance – the genomic and other changes that occur that allow the cancer to begin growing again – are largely unknown. This study sought to identify them.”

“Given the high prevalence of KRAS driven cancers and resulting unmet medical need, elucidating the genetic underpinnings of acquired resistance to KRAS inhibitors at the time of progression is critical,” Mark Li, CEO of Resolution Bioscience, said. "Importantly, in this study, more than three times as many patients were able to be genotyped by cfDNA compared to tissue alone at the time of progression. Furthermore, this study highlights the importance for cfDNA assays to accurately detect all major types of genetic aberrations, including gene fusions and copy number variations.”

Agilent's Resolution Bioscience team has partnered with Mirati Therapeutics Inc. (NASDAQ: MRTX) to use the Resolution ctDx FIRST assay as a companion diagnostic (CDx) in support of adagrasib for identifying patients with non-small cell lung cancer patients that harbor a KRAS G12C mutation. Liquid biopsy biomarker testing of patients in the adagrasib registrational clinical trial is being performed in Resolution’s clinical lab based in Kirkland, Washington.

About Agilent Technologies

Agilent is a leader in life sciences, diagnostics, and applied chemical markets, delivering innovative technology solutions that provide trusted answers to researchers’ most challenging scientific questions. The company generated revenue of $5.34 billion in fiscal year 2020 and employs 16,400 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, please subscribe to the Agilent Newsroom. Follow Agilent on LinkedIn, Twitter, and Facebook.


ę Business Wire 2021
All news about AGILENT TECHNOLOGIES, INC.
11/23Agilent to Present at Evercore ISI Virtual Healthcare Conference
BU
11/23Stifel Adjusts Price Target for Agilent Technologies to $169 From $162, Maintains Hold ..
MT
11/23SVB Leerink Adjusts Agilent Technologies' Price Target to $175 from $170, Keeps Outperf..
MT
11/23Health Care Stocks Flat Ahead of Tuesday's Opening Bell
MT
11/22AGILENT TECHNOLOGIES : Prepared Remarks (opens in new window)
PU
11/22AGILENT : Fiscal Q4 Earnings Snapshot
AQ
11/22Agilent Technologies Fiscal Q4 non-GAAP EPS, Revenue Rise
MT
11/22AGILENT TECHNOLOGIES : Reports Fourth-Quarter and Fiscal Year 2021 Financial Results - For..
PU
11/22Earnings Flash (A) AGILENT TECHNOLOGIES Posts Q4 Revenue $1.66B, vs. Street Est of $1.6..
MT
11/22Agilent Reports Fourth-Quarter and Fiscal Year 2021 Financial Results
BU
More news
Analyst Recommendations on AGILENT TECHNOLOGIES, INC.
More recommendations
Financials (USD)
Sales 2021 6 318 M - -
Net income 2021 1 075 M - -
Net Debt 2021 1 485 M - -
P/E ratio 2021 42,8x
Yield 2021 0,51%
Capitalization 45 206 M 45 206 M -
EV / Sales 2021 7,39x
EV / Sales 2022 6,82x
Nbr of Employees 17 000
Free-Float 100,0%
Chart AGILENT TECHNOLOGIES, INC.
Duration : Period :
Agilent Technologies, Inc. Technical Analysis Chart | A | US00846U1016 | MarketScreener
Technical analysis trends AGILENT TECHNOLOGIES, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 16
Last Close Price 149,33 $
Average target price 173,80 $
Spread / Average Target 16,4%
EPS Revisions
Managers and Directors
Michael R. McMullen President, Chief Executive Officer & Director
Robert W. McMahon Chief Financial Officer & Senior Vice President
Boon Hwee Koh Non-Executive Chairman
Darlene J. S. Solomon Chief Technology Officer & Senior Vice President
Katharine Knobil Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
AGILENT TECHNOLOGIES, INC.25.08%45 206
THERMO FISHER SCIENTIFIC36.57%250 658
DANAHER CORPORATION40.88%223 620
INTUITIVE SURGICAL, INC.20.03%114 898
SIEMENS HEALTHINEERS AG52.50%80 761
EDWARDS LIFESCIENCES CORPORATION20.38%67 728